trial

Treatment to Enhance Cognition in Bipolar Disorder

NCTId NCT01470781
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 72 (actual)
Sponsored by Mclean Hospital
Primary completion 2016-08-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
72 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-06
Primary completion
2016-08-01
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
BrainWorks

Sponsors

Mclean HospitalLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Kathryn E Lewandowski, Ph.D.Principal Investigator

Sites

1 total
Belmont, United States

Facts & assertions

4 sourced
Enrollment
72
Phase
NA
Primary Completion Date
2016-08-01
Status
COMPLETED
relationships
The graph out of here
drug
BrainWorks
drug
lead_sponsor
Mclean Hospital
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Bipolar Disorder
indication
Bipolar Disorder
indication
Psychosis
indication
investigator
Kathryn E Lewandowski, Ph.D.
person